Key Facts
• September 2023: Ex-hospital staff reported improper drug use to compliance department.
• Allegation: Overuse of labor-inducing drug “Atorin” against medical guidelines.
• 1.5 years: Whistleblower claims no progress beyond “under investigation” response.
• September 16, 2025: City council health committee held discussions on the issue.
• City officials: Investigation followed proper procedures but lacked medical expertise.
• Officials clarified: Deviating from guidelines does not always breach legal obligations.
• City stated: Public health office oversees hospital compliance under medical law.
• Whistleblower submitted a request for re-investigation with medical evaluation.
• No prior compliance issues flagged by public health office for the hospital.
Summary
Saitama City faces scrutiny over claims of mishandling a whistleblower report regarding improper drug use at a municipal hospital. The report, filed in September 2023, alleged excessive use of the labor-inducing drug “Atorin” against medical guidelines. Despite providing evidence, the whistleblower received no substantial updates for 1.5 years. During a city council meeting on September 16, 2025, officials stated the case was handled appropriately but admitted no medical experts were involved in the investigation. They emphasized that deviating from medical guidelines does not necessarily constitute a legal violation. The city clarified that hospital compliance oversight falls under the public health office, which has not flagged any issues. The whistleblower has since requested a re-investigation with a focus on medical evaluation.
